Colorectal - oncology - SA Health Approved Cancer Chemotherapy Protocol Register
Adjuvant and neoadjuvant
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Adjuvant CAPOX (XELOX) (capecitabine and oxaliplatin) | Medium | February 2023 |
Colorectal adjuvant capecitabine The SA Health Cancer Drug Committee has approved this protocol for use for the additional indication: Adjuvant high risk stage II proficient mismatch repair colorectal cancer after complete resection of the primary tumour. |
Low | February 2023 |
Colorectal adjuvant de Gramont (modified) (fluorouracil and leucovorin) | Low | February 2023 |
Colorectal adjuvant FOLFOX6 (Modified) (fluorouracil leucovorin oxaliplatin) The SA Health Cancer Drug Committee has approved this protocol for the additional indication: Neoadjuvant therapy prior to definitive surgery. |
Medium2 | February 2023 |
Colorectal adjuvant QUASAR (Modified) fluorouracil leucovorin weekly | Low | February 2023 |
Metastatic
Anal
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Anal advanced cARBOplatin and PACLitaxel | Medium | February 2024 |
Anal definitive cISplatin and fluorouracil chemoradiation | Medium2 | February 2027 |
Anal definitive mitomycin and capecitabine chemoradiation | Medium | February 2023 |
Anal definitive mitomycin and fluorouracil chemoradiation | Medium2 | February 2023 |
Rectal
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Adjuvant CAPOX (XELOX) (capecitabine and oxaliplatin) | Medium | February 2023 |
Rectal locally advanced capecitabine chemoradiation | Medium | February 2027 |
Rectal locally advanced fluorouracil (protracted Infusion) chemoradiation | Medium2 | February 2023 |
Rectal neoadjuvant CAPOX (XELOX) (capecitabine and oxaliplatin) The SA Health Cancer Drug Committee have approved this protocol for the amended indication: Neoadjuvant treatment of patients with stage II or III rectal cancer (up to 8 cycles) |
Medium | February 2023 |
Rectal adjuvant FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) | Medium | February 2023 |
Rectal neoadjuvant FOLFIRINOX (modified) (fluorouracil leucovorin irinotecan oxaliplatin) | Medium2 | August 2023 |
Rectal neoadjuvant FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) The SA Health Cancer Drug Committee have approved this protocol for the amended indication: Neoadjuvant treatment of patients with stage II or III rectal cancer (up to 12 cycles) |
Medium | February 2023 |
Notes
- Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
- Fluorouracil pumps may be connected/disconnected at low-risk units
- Non-formulary drug included in the protocol
- Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.